However, our study reinforces the conclusion (5) that, since both fingolimod (53) and gefitinib (54) are FDA-approved drugs (though not for breast cancer), inhibiting IGFBP-3-dependent oncogenic signaling by F + G therapy is a plausible approach to targeting basal-like TNBC tumors. Here, IGFBP3 is linked to breast carcinoma.